Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis

Table 2 Crude incidence rate of dementia with allopurinol versus febuxostat exposure

	Person-days of follow-up	Number of cases of incident dementia	Dementia incidence rate per 100,000 person-days
Allopurinol	16,999,091	1593	10
Febuxostat	774,291	62	9
Allopurinol duration
1–180 days	7,775,101	834	11
181–365 days	3,311,650	286	9
>1 year	5,912,340	473	9
Febuxostat duration
1–180 days	435,872	35	9
181–365 days	167,335	14	9
>1 year	171,084	13	8
Allopurinol dose
< 200 mg/day	7,701,139	899	12
200–299 mg/day	3,091,767	251	9
≥300 mg/day	6,206,185	443	8
Febuxostat dose
40 mg/day	634,925	51	9
80 mg/day	139,366	11	8

*Drug exposure considered up to 30 days after last day of medication fill/refill (except when switched to the other ULT, i.e., switched from allopurinol to febuxostat or vice versa); baseline period was 365 days, that is, each new exposure was defined as no previous exposure (allopurinol or febuxostat) in the baseline period

ISSN: 1478-6362